BridgeMD
New treatment option for Solid Cancer
Official title TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
ClinicalTrials.gov ID: NCT07242417
What this study is testing
What is TC-G203 cells treatment?
TC-G203 cells treatment is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for solid cancer.
Also referred to as Cyclophosphamide, Fludarabine.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-G203 in patients with GPC3-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Participants must voluntarily provide written informed consent.
- Aged 18-75 years (inclusive).
- Life expectancy ≥ 12 weeks.
- ECOG performance status 0-1.
- Failed or unsuitable for standard therapy.
You likely can't join if
- Primary CNS malignancy or uncontrolled CNS metastases.
- Other malignancies within 5 years
- Active autoimmune disease or history of autoimmune disease.
- Immunodeficiency, including HIV positivity
- Bleeding disorders (inherited or acquired).
- Clinically significant cardiovascular disease.
See the full eligibility criteria
- Participants must voluntarily provide written informed consent.
- Aged 18-75 years (inclusive).
- Life expectancy ≥ 12 weeks.
- ECOG performance status 0-1.
- Failed or unsuitable for standard therapy.
- At least one measurable lesion per RECIST 1.1.
- GPC3-positive tumor confirmed by immunohistochemistry.
- Adequate organ and bone marrow function.
- Effective contraception required for participants of childbearing potential.
- Adequate venous access for leukapheresis.
- Primary CNS malignancy or uncontrolled CNS metastases.
- Other malignancies within 5 years
- Active autoimmune disease or history of autoimmune disease.
- Immunodeficiency, including HIV positivity
- Bleeding disorders (inherited or acquired).
- Clinically significant cardiovascular disease.
- Active infection (including tuberculosis, hepatitis C, syphilis).
- Pregnant or breastfeeding women.
- Severe systemic or psychiatric illness.
- Prior cell or gene therapy.
- Severe drug hypersensitivity history.
- Investigator-assessed unsuitability for trial participation. -
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.